The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Aligning Science Across Parkinson's, 2021Basal Ganglia Networks in Parkinson's Disease
Study Rationale:
People with Parkinson's disease have long been known to display remarkable motor abilities under special circumstances such as smooth walking with certain visual or auditory cues... -
Aligning Science Across Parkinson's, 2021Distributed Circuit Dysfunction Underlying Motor and Sleep Deficits in a Progressive Model of Parkinson’s Disease
Study Rationale:
Parkinson’s disease (PD) begins decades before it compromises the ability to move about in the world and sleep through the night. Understanding how the dysfunction of brain circuits... -
Aligning Science Across Parkinson's, 2021Activity and Connectivity Drive Neuronal Vulnerability and Disease Progression in Parkinson’s Disease
Study Rationale:
Specific brain circuits that are highly melanized (build-up of the dark pigment neuromelanin) with age are primarily affected, particularly early, in Parkinson's disease. Models... -
Aligning Science Across Parkinson's, 2021Cortical Pathophysiology of Parkinsonism
Study Rationale:
The outer mantle of the brain, the cerebral cortex, plays a significant role in selecting and controlling movements. Changes in the activity of cortical neurons are key to disorders... -
Research Grant, 2021Development of Alpha-synuclein and Tau Imaging Agents
Study Rationale: Accumulation of alpha-synuclein and tau protein aggregates are pathological hallmarks of Parkinson’s disease (PD) and Frontal Temporal Dementia (FTD), respectively. The appearance of...
-
Outcome Measures, 2021Development of a Method for Assessing the Effectiveness of Alpha-synuclein Immunotherapy
Study Rationale: Parkinson’s disease (PD) is characterized by the buildup of misfolded forms of alpha-synuclein. A vaccine designed to target this abnormal protein has demonstrated safety...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.